Skip to main content

Table 3 Diagnostic accuracy of proteolytic enzymes, CEA and CA 19-9 in colorectal cancer.

From: Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

 

CATB

CATL

uPA

PAI-1

CEA

CA 19-9

Cut-off

(4.60)

(1.12)

(0.21)

(18.90)

(4.0)

(37.0)

Sensitivity (%)

82

41

69

94

30

18

Specificity (%)

88

80

82

84

89

93

PPV (%)

82

58

72

79

65

62

PPV-Positive Prevalence (%)

43

19

33

40

26

23

NPV (%)

88

68

80

96

66

63

NPV-Negative Prevalence (%)

27

7

19

35

5

2

Accuracy (%)

86

65

77

88

66

63

Fisher's Exact Test

P< 0.0001

P= 0.008

P< 0.0001

P< 0.0001

P= 0.004

P= 0.06

  1. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer
  2. Abbreviations: PPV: Positive predictive value; NPV: Negative predictive value; CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: plasminogen activator inhibitor type-1; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9; Cut-off: cut-off values expressed in ng/ml; Positive Prevalence: the percentage of tumor patients in all patient groups investigated, i.e. 56/142 = 39%; Negative Prevalence: the percentage of non-tumor individuals in all patient groups investigated, i.e. 86/142 = 61%; PPV-Positive Prevalence: the difference between PPV and positive prevalence; NPV-Negative Prevalence: the difference between NPV and negative prevalence